Citius Oncology Inc. reported its full year (FY) financial results for the period ending September 30, 2025. The company posted an accumulated deficit of USD 64.0 million and had no revenue for the period. As of September 30, 2025, Citius Oncology Inc. reported cash holdings of USD 3.9 million and a negative working capital of approximately USD 21.9 million. During the fiscal year, the company raised net proceeds of approximately USD 15 million from equity offerings. Citius Pharma, the parent company, also raised net proceeds of approximately USD 32 million from equity offerings and USD 1 million from a note payable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-125331), on December 23, 2025, and is solely responsible for the information contained therein.